Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

+pharma arzneimittel gmbh - lenalidomid -

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

+pharma arzneimittel gmbh - lenalidomid -

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

+pharma arzneimittel gmbh - lenalidomid -

Europäische Union - Deutsch - EMA (European Medicines Agency)

mylan ireland limited - lenalidomid - multiples myelom - immunsuppressiva - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).

Europäische Union - Deutsch - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - immunsuppressiva - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ist indiziert für die behandlung erwachsener patienten mit zuvor unbehandeltem multiplen myelom, die nicht die voraussetzungen für eine transplantation. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

ever valinject gmbh - bortezomib -

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - bortezomibum - lyophilisat zur herstellung einer injektionslösung - vorbereitung cryodesiccata: bortezomibum 3,5 mg, mannitolum, für glas. - zytostatikum - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - bortezomibum - lyophilisat zur herstellung einer injektionslösung - vorbereitung cryodesiccata: bortezomibum 1 mg, mannitolum, für glas. - zytostatikum - synthetika

Europäische Union - Deutsch - EMA (European Medicines Agency)

accord healthcare s.l.u. - lenalidomid - multiples myelom - immunsuppressiva - multiple myelomalenalidomide accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) ist indiziert für die behandlung erwachsener patienten mit zuvor unbehandeltem multiplen myelom, die nicht die voraussetzungen für eine transplantation. lenalidomid accord in kombination mit dexamethason ist indiziert für die behandlung des multiplen myeloms bei erwachsenen patienten, die erhalten haben, mindestens eine vorherige therapie. follicular lymphomalenalidomide accord in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - bortezomibum - pulver zur herstellung einer injektionslösung - bortezomibum 1 mg, mannitolum, für glas. - zytostatikum - synthetika